

# Myelin oligodendrocyte glycoprotein antibody-associated disease

---

Younes, Aya

Master's thesis / Diplomski rad

2022

Degree Grantor / Ustanova koja je dodijelila akademski / stručni stupanj: **University of Zagreb, School of Medicine / Sveučilište u Zagrebu, Medicinski fakultet**

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:105:448687>

Rights / Prava: [In copyright](#) / [Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2025-01-19**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine Digital Repository](#)



**UNIVERSITY OF ZAGREB  
SCHOOL OF MEDICINE**

**Aya Younes**

**Myelin oligodendrocyte glycoprotein  
antibody-associated disease**

**GRADUATE THESIS**



**Zagreb, 2022**

This graduation paper was made at The Division of Neurology Department of Paediatrics in University Hospital Centre Zagreb and under the supervision of Prof. dr. sc. Nina Barišić, dr. med. It was submitted for evaluation in the academic year 2021/2022.

## List of Abbreviations

ADCC- antibody-dependent cellular cytotoxicity  
ADEM- acute disseminated encephalomyelitis  
AFM- acute flaccid myelitis  
APC-antigen presenting cells  
AQP4-4-aquaporin 4  
AZA-azathioprine  
CBC- complete blood count  
CIDP-Chronic inflammatory demyelinating peripheral neuropathy  
CNS- central nervous system  
CRION-chronic relapsing inflammatory optic neuropathy  
EDSS-expanded disability status scale  
FLAIR- fluid-attenuated inversion recovery  
FLAMES- FLAIR-hyperintense lesions in anti-MOG associated encephalitis with seizures.  
HEK293- human embryonic kidney cells  
HNK-1- human natural killer-1  
IPMSSG-international pediatric multiple sclerosis study group  
IVG-immunoglobulin variable  
IVIG-intravenous immunoglobulin  
IVMP-intravenous methylprednisone  
LETM-longitudinal extensive transverse myelitis  
MAG-myelin associated glycoprotein  
MBP-myelin basic protein  
mGCPIL- macular ganglion cell layer and inner plexiform layers  
MHC-major histocompatibility complex  
MOGAD-myelin oligodendrocyte glycoprotein antibody-associated disease  
MOG-myelin oligodendrocyte glycoprotein  
MS-multiple sclerosis  
NBD-Neuro Bechet disease  
NMDAR-N-methyl-D-aspartate receptor encephalitis  
NMO-neuromyelitis optica  
NMOSD-neuromyelitis optica spectrum disorder  
OCS-oral corticosteroids  
OCT-optical coherence tomography  
ON- optic neuritis  
PF-prolonged fever

PLP-proteolipid protein

PNS- peripheral nervous system

pRNFL- peripapillary retinal nerve fiber layer

RTX-rituximab

SPECT-single photon emission computed tomography

TM-transverse myelitis

## Table of contents

SUMMARY.....	1
SAŽETAK.....	2
1. Introduction.....	3
2. Pathogenesis.....	3
2.1. MOG structure and function.....	3
2.2. MOG antibody.....	4
2.3. Pathology.....	4
3. Epidemiology.....	5
4. Clinical features.....	5
4.1. Optic neuritis.....	6
4.2. ADEM.....	6
4.3. Transverse myelitis.....	7
4.4. AQP4 seronegative NMOSD.....	8
4.5. Cerebral cortical encephalitis.....	8
4.6. Brainstem and cerebellar lesions.....	9
4.7. Other clinical features.....	9
4.8. Overlapping syndromes.....	10
4.9. Association with COVID-19.....	11
5. Evaluation and diagnosis.....	11
5.1. When to screen for MOGAD.....	11
5.2. Diagnostic criteria.....	12
5.3. Investigation methods.....	12
5.3.1 Cell-based assay.....	12
5.3.2 Cerebrospinal fluid analysis.....	13
5.3.3 MRI findings.....	13
5.3.4 Optical coherence tomography (OCT).....	15
6. Differential diagnosis.....	15
7. Treatment.....	16
7.1. Acute attacks.....	16
7.2. Attack prevention.....	17
8. Prognosis.....	20
9. Conclusion.....	21
10. Acknowledgements.....	21
11. References.....	21
12. Biography.....	38

## **Summary**

Author: Aya Younes

Myelin oligodendrocyte glycoprotein (MOG) associated disease (MOGAD) is a rare antibody-mediated inflammatory demyelinating disorder of the central nervous system (CNS) characterized by a spectrum of phenotypes including optic neuritis (ON), acute demyelinating encephalomyelitis (ADEM), transverse myelitis (TM), and cortical encephalitis. Even though the clinical manifestations of MOGAD are similar to those of neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS), the widespread use of novel cell-based assays has enabled experts to recognize MOGAD as a distinct entity with different immunological pathogenesis. MOG is primarily expressed in the CNS and is located on the outer membrane of myelin sheaths. This glycoprotein's function is not fully understood; however, it may serve as a regulator of microtubular stability, cell surface receptor, or mediator of myelin fiber adhesion. Its position on the outermost surface of oligodendrocytes makes it an accessible target for autoantibodies that cause pathological alterations. Optic neuritis appears to be the most common initial manifestation in adults, whereas ADEM is most prevalent in children. The disease can either be monophasic or relapsing, the latter associated with ON as the initial assault, older age at onset, or persistence of MOG-Immunoglobulin-G (IgG) seropositivity. Despite this, demyelinating lesions on T2 MRI frequently remit, with secondary progression rarely linked to MOGAD, in contrast to MS, which typically has clinically silent residual, relapsing-remitting, and progressive lesions on MRI. Observational open-label experience indicates a need for high-dose intravenous (IV) steroids, (IV) immunoglobulins (IVIg), and plasma exchange in conjunction or alone in treating severe acute attacks. For maintenance therapy, chronic immunosuppressive medications, including oral steroids, oral immunosuppressants, and rituximab, are appropriate. Interestingly, MOGAD patients have more favorable outcomes than those with multiple sclerosis or aquaporin-4-IgG-NMOSD (AQP4-IgG-NMOSD), yet additional incident case studies are required to optimize treatments for relapse prevention.

Keywords: MOGAD, MOG, myelin oligodendrocyte glycoprotein antibody, encephalitis, optic neuritis, multiple sclerosis.

## **Sažetak**

Bolest povezana s mijelinskim oligodendrocitnim glikoproteinom (MOG) (MOGAD) je rijedak upalni demijelinizirajući poremećaj središnjeg živčanog sustava (SŽS) posredovan antitijelima koji je karakteriziran spektrom fenotipova uključujući optički neuritis (ON), akutni demijelinizirajući encefalomijelitis (ADEM), transverzalni mijelitis (TM), i kortikalni encefalitis. Iako su kliničke manifestacije MOGAD-a slične onima neuromijelitisa optičkog spektra (NMOSD) i multiple skleroze (MS), široko rasprostranjena uporaba novih staničnih testova omogućila je stručnjacima da prepoznaju MOGAD kao poseban entitet s različitom imunološkom patogenezi. MOG se prvenstveno izražava u CNS-u i nalazi se na vanjskoj membrani mijelinskih ovojnica. Funkcija ovog glikoproteina nije u potpunosti shvaćena; međutim, može poslužiti kao regulator stabilnosti mikrotubula, receptor na staničnoj površini ili posrednik adhezije mijelinskih vlakana. Njegov položaj na krajnjoj vanjskoj površini oligodendrocita čini ga dostupnim ciljem za autoantitijela koja uzrokuju patološke promjene. Čini se da je optički neuritis najčešća početna manifestacija u odraslih, dok je ADEM najčešći u djece. Bolest može biti monofazna ili relapsirajuća, pri čemu je potonja povezana s ON kao početnim napadom, starijom dobi na početku ili postojanošću seropozitivnosti na MOG-Imunoglobulin-G (IgG). Unatoč tome, demijelinizirajuće lezije na T2 MRI često se povuku, sa sekundarnom progresijom rijetko povezanom s MOGAD-om, za razliku od MS-a, koja obično ima klinički tihe rezidualne, relapsno-remitentne i progresivne lezije na MRI. Opservacijsko otvoreno iskustvo ukazuje na potrebu za visokom dozom intravenskih (IV) steroida, (IV) imunoglobulina (IVIg) i/ili izmjenom plazme u liječenju teških akutnih napada. Za terapiju održavanja prikladni su kronični imunosupresivni lijekovi, uključujući oralne steroide, oralne imunosupresive i rituksimab. Zanimljivo je da pacijenti s MOGAD-om imaju povoljnije ishode od onih s multiplom sklerozom ili akvaporin-4-IgG-NMOSD (AQP4-IgG-NMOSD), no potrebne su dodatne studije slučaja kako bi se optimizirali tretmani za prevenciju recidiva.

Ključne riječi: MOGAD, MOG, mijelinsko oligodendrocitno glikoproteinsko protutijelo, encefalitis, optički neuritis, multipla skleroza.



## **1. Introduction**

Myelin oligodendrocyte glycoprotein (MOG), a surface protein on oligodendrocytes, was initially thought to be a possible antibody target in MS(1); however, early investigations were equivocal. Using immunoblot and enzyme-linked immunosorbent assay, anti-MOG-antibodies were identified in a subset of patients with ADEM but only rarely in adult patients with multiple sclerosis(2). Later, newer generation of cell-based assays were developed and further identified MOG-Abs in adults and in children with ADEM, anti- aquaporin-4-antibody (AQP4-Ab)-seronegative NMOSD, optic neuritis, transverse myelitis, and other associated conditions. Thus, myelin oligodendrocyte-associated disease has been confirmed as a separate demyelinating disease of the central nervous system(3). This article examines MOGAD's epidemiology, pathogenesis, clinical signs and symptoms, diagnosis, therapy, and prognosis.

## **2. Pathogenesis**

### **2.1. MOG structure and function**

The myelin sheath surrounds large axons in the central nervous system and the peripheral nervous system (PNS) to allow rapid conduction of action potential. In the CNS, the myelin-forming cells are the oligodendrocytes, and the extension of their plasma membrane (oligodendrocyte processes) serves as the insulator sheath(4). The myelin oligodendrocyte glycoprotein is located on the outermost layer of the oligodendrocyte processes. Other proteins expressed by oligodendrocytes include the myelin basic protein (MBP), proteolipid protein (PLP), and myelin-associated glycoprotein (MAG). The interaction between these glycoproteins serves a role in forming and maintaining the myelin's structural integrity. (5,6)

MOG is a minor component of the myelin sheath and yet is thought to have several important functions, such as regulating oligodendrocyte microtubule stability and maintaining the myelin sheath's structural integrity via adhesion features, and mediating interactions between myelin and the immune system (7). In several experimental studies, significant loss of MBP was noted in the presence of anti-MOG antibodies, whereas antibodies to other myelin components, such as MBP and MAG, were ineffective in causing such MBP degradation. MOG and MAG are glycosylated with Human Natural Killer-1 (HNK-1) epitopes in oligodendrocytes(8). These epitopes on nerve cells play an essential role in myelin's structure and function as they are linked to cell migration, neuron-to-glia cell contact, and astrocytic process outgrowth (9). Therefore, the idea that MOG is involved in adhesion between adjacent myelin fibers becomes more acceptable.

Expressed only in mammals, MOG is composed of a signal peptide of 29 amino acids followed by 218 amino acids of the mature protein(10). As an Immunoglobulin superfamily member, it is highly immunogenic(7). It consists of an extracellular immunoglobulin variable (IgV) domain, transmembrane hydrophobic domain, cytoplasmic loop, and a second hydrophobic domain near the membrane, followed by a cytoplasmic end. The outermost location on the myelin sheath and the extracellular component makes MOG an accessible target for potential antibodies, resulting in demyelination (11).

MOG's role in the pathogenesis of demyelinating disorders can be supported because the MOG gene is located on the major histocompatibility complex (MHC) locus. This region encodes molecules expressed on cells involved in antigen presentation, inflammation activation, and innate and adaptive immunity initiation(10). Moreover, the gene shares structural similarities with the B7-CD28 superfamily, which encodes for proteins found on the surface of professional antigen-presenting cells (APC). This further supports that MOG has an immunogenic role in demyelinating processes(12).

## **2.2. MOG antibody**

Human's MOG-IgG potential pathogenic activity was supported before by in vitro experiments: antibodies to MOG are typically of IgG1 isotypes, proven to promote complement-mediated cellular death(13,14). Notably, circulating MOG antibodies alone do not promote inflammation and neurodegeneration in normal animals(15). However, in animal models, antibodies obtained from anti-MOG NMO may elicit inflammatory demyelination in vivo or in vitro after direct injection into the cerebrospinal fluid (CSF) or brain tissue of mice with T-cell mediated autoimmune encephalomyelitis(16,17). In vivo, MOG antibodies reach the central nervous system (CNS) in the setting of inflammation, as the blood-brain barrier breaks down, allowing their passage to the CNS.(15,18,19).

## **2.3. Pathology**

The pathogenesis of MOGAD has been illuminated by autopsies and biopsies obtained from confirmed disease cases(20,21). According to these studies, MOGAD pathology is characterized by the coexistence of perivenous and confluent demyelination in the white and grey matter, with a higher incidence of intracortical demyelinating lesions. Inflammation is characterized by CD4-positive T cells and granulocytic infiltration, unlike MS, which predominantly consists of CD8-positive T cell inflammation.

A perivascular pattern of complement deposition is also noted in MOGAD cases, which differs from AQP4-IgG-NMOSD, where complement deposits colonize astrocytes of the glia limitans where AQP4 is expressed(20). The astrocytic damage is a distinctive feature

of AQP4-IgG-NMOSD, as AQP4 expression is mainly preserved in MOGAD patients. Although the selective loss of MOG is expected, only one case to date demonstrated such findings(21). Therefore, it is hypothesized that upon anti-MOG antibody binding to the MOG epitope, the whole myelin is destroyed either by complement or antibody-dependent cellular cytotoxicity (ADCC) phagocytosis. For selective loss of MOG antigen to occur, binding of MOG antibody would have to induce endocytic internalization of MOG antigen into the cell(20). In seropositive NMOSD, AQP4-IgG targets the AQP4-antigen primarily by this mechanism(22).

### **3. Epidemiology**

MOGAD has only recently been recognized as a distinct clinical entity from other autoimmune demyelinating disorders, so epidemiological data are limited.

According to a study in the Netherlands, with collected samples between 2014 and 2017, MOGAD incidence was 1.6 per million person-years(23). In the UK, a study concluded an incidence of 3.4 per million person-years(24). When compared to AQP4-IgG NMOSD, the frequency of MOGAD varies by region. MOGAD is more common in Sri Lanka and the United Kingdom(23–25), whereas AQP4-IgG NMOSD appears more prevalent in Korea (26). Additionally, compared to higher cases reported among East Asians and Africans and a strong association with HLA observed in AQP4-IgG-NMOSD(27), MOGAD showed no ethnic tendency or HLA association(28).

Female predominance is typical in autoimmune diseases. Indeed in both MS and NMOSD, the ratio between females and males is 1.4:1 to 2.3:1 and 9:1, respectively (27,29). However, no significant sex differences were noted with anti-MOG-positive patients (24).

MOGAD has a variable onset age between 20 and 30, with the highest prevalence among children. A study in Israel examined how the age of onset affects the disease's course. They reported that early-onset MOGAD (<18 years) and late-onset MOGAD (>50 years) both had a monophasic course (14/20 and 3/3, respectively), while most young adults (64 % of patients aged 30–40 years) had a recurrent disease (30).

### **4. Clinical features**

The autoimmune response to MOG results in nonspecific clinical features that overlap with those seen in MS and NMOSD. The most commonly observed are acute attacks of optic neuritis, acute disseminated encephalomyelitis, and transverse myelitis (30–32). The

attacks can be preceded by an infectious illness or vaccination and usually develop over days with varying recovery times(33,34) and subsequently can be either monophasic or relapsing, depending on the symptom and the onset of age(30). As we delve deeper into each clinical sign and symptom, distinct entities that are MOGAD-related emerge.

#### **4.1. Optic neuritis**

Inflammation of the optic nerve and its covering (ON) is the most common presenting symptom in adults with anti-MOG antibodies(32). The acute attack typically manifests bilaterally with significant visual impairment and eye pain, especially with movement(35). Caution is advised when examining a child because the inflammation is usually unilateral and can be misinterpreted as a nonspecific headache(36). Optic neuritis manifests similarly in other demyelinating disorders; however, apparent differences remain from MS and AQP4-IgG-NMOSD, suggesting MOGAD is a separate diagnosis. Using the expanded disability status scale (EDSS) score, one study demonstrates that visual impairment is more severe than MS or NMOSD but has favourable outcomes when reevaluated after a follow-up period. Compared to AQP4-antibody-positive patients, the EDSS scores of MOGAD patients decreased significantly(37).

Fundoscopy may detect more prevalent unilateral or bilateral optic disc edema than in MS but similarly to bilateral involvement as seen in AQP4-IgG NMOSD . When bilateral, it may be confused with papilledema caused by increased intracranial pressure (35). Despite this, an MRI is sufficient for exclusion and will typically reveal anterior and longitudinal inflammation of the optic nerve(37,38). According to some studies, those with optic neuritis as their initial symptom are more likely to develop a relapsing form of the disease with a higher recurrence rate(16,32). As the primary treatment, an inadequate corticosteroid treatment cycle( $\leq 3$  months) can also increase the likelihood of relapse(32). As the patient develops recurrent episodes of optic neuritis, chronic relapsing inflammatory optic neuropathy (CRION) is diagnosed(39,40).

#### **4.2. ADEM**

Acute disseminated encephalomyelitis is an immune-mediated demyelinating disease that predominantly affects children and young adults. In ADEM-diagnosed children, up to 68% develop antibodies to MOG, making it the most common initial presentation (41). Ataxia, dysarthria, seizures, altered sensorium, and behavioural abnormalities, including confusion and agitation, are just a few of the symptoms that can appear suddenly, corresponding to the affected area of the central nervous system. According to the International Paediatric Multiple Sclerosis Study Group (IPMSSG), ADEM is diagnosed if the following criteria are met: first clinical CNS event with the suspected demyelinating

origin, encephalopathy that cannot be explained by fever or systemic illness, and abnormal brain MRI during the acute phase that is compatible with ADEM but not indicative of any other CNS disease (42). In ADEM, lesions are large, poorly demarcated, and bilaterally distributed which differ from MS, where lesions are typically smaller, well-demarcated, and predominantly localized periventricularly in the white matter supra and infratentorial but also cortically and subcortically especially in the corpus callosum (43,44). While most develop a monophasic course of the disease, a small group of patients experience repeated ADEM attacks and are diagnosed with multiphasic ADEM. López-Chiriboga et al. investigated the relationship between such relapse and persistent MOG-IgG. Recurrence was observed in 88% of patients with constant MOG-IgG positivity, whereas only one of eight patients with transiently positive antibodies had the same outcome (44).

Another study compared paediatric patients' clinical presentation and prognosis of acquired demyelinating syndromes associated with MOG antibodies to those without anti-MOG antibodies. Results demonstrated no clinical symptoms, gender ratio, or age changes, except for a greater white blood cell count in cerebrospinal fluid (CSF) and behavioural issues at initial presentation in anti-MOG-positive patients (45).

When evaluating the MRI data, both groups of patients exhibited large bilateral lesions; however, the spinal cord was more commonly affected in children with MOG antibodies, with lesions extending longitudinally in more than three segments, a condition known as longitudinal extensive transverse myelitis (LETM) (45). Cobo-Calvo's study produced similar results, demonstrating that thalamic and brainstem involvement are distinct signs of MOGAD (46). Worthy of note is that, in most children with MOGAD, the MRI alterations disappeared during a follow-up MRI examinations, and patients included in treatment protocol for MOGAD experienced improved clinical outcomes(37,47).

Resolution and rapid recovery typical for MOGAD are related to the fact that MOG is expressed on mature oligodendrocytes rather than on progenitor cells; hence rapid recruitment of new oligodendrocytes ensues. Nonetheless, several studies indicate that the resolution of a lesion on an MRI does not necessarily mean a favourable prognosis, as up to forty percent of patients demonstrated long-term cognitive impairment (32). Additionally, one study revealed that children who tested positive for MOG-IgG were more likely than their non-MOG-IgG counterparts to develop post-disease epilepsy(48).

### **4.3. Transverse myelitis**

Transverse myelitis is an acute inflammation of the spinal cord parenchyma that causes motor, sensory, and autonomic impairment(49). TM is a common presenting sign in adult

MOGAD patients, and it can occur alone or in conjunction with ADEM or optic neuritis(50–52). The inflammatory condition is characterized by extensive longitudinal demyelination located centrally and encompassing more than three contiguous segments, with the most frequently affected cervical and thoracic spinal cords(53). MS, on the other hand, affects fewer than three segments, with lesions typically located posteriorly. Classic symptoms are partial or complete lower extremity paralysis with hypoesthesia below the lesion site and across the sensory level of the torso(54). In most cases, involvement of the medullary conus occurs, which causes urinary, bowel, and erectile dysfunction. In some instances, demyelination affecting the posterior part of the medulla and cervical cord is suspected if flexion of the neck elicits an electrical sensation spreading to the extremities, a phenomenon known as the Lhermitte(50,51).

#### **4.4. AQP4 seronegative NMOSD**

The clinical criteria for NMOSD include an episode of optic neuritis, transverse myelitis, or area postrema syndrome; and a second episode of one of the conditions mentioned or a brainstem, diencephalic, or other cerebral syndromes (55). Even with the most sensitive assays, AQP4-IgG is not detected in about 25% of patients who met the criteria for NMOSD. Given that neuromyelitis optica spectrum disorder is rarely associated with false negatives, it is likely that a different disease with overlapping clinical symptoms is the cause of such findings(56). In fact, 15 to 40 percent of AQP4-IgG-NMOSD-seronegative patients had MOG-IgG(57–60). These represent only about a third of the entire MOGAD population, underlining the need for MOGAD-specific diagnostic criteria.

#### **4.5. Cerebral cortical encephalitis**

Ogawa first reported a new anti-MOG phenotype known as cerebral cortical encephalitis in 2017(61). Since then, 21 cases have been reported, manifesting with cortical inflammation and seizure attacks. According to Wang's review, most affected patients were males (72.6%) with an onset of age averaging 26.8 years. Symptoms include fever, headache, hemiparesis, hemianopsia, aphasia, memory deficits, and psychiatric problems. Cortical inflammation was primarily unilateral and associated with swelling and hyperintense lesions on the MRI FLAIR sequence without white matter involvement. Some have referred to these occurrences as "unilateral cortical fluid-attenuated inversion recovery (FLAIR)-hyperintense lesions in anti-MOG-associated encephalitis with seizures" with the abbreviation FLAMES(62). Following treatment with corticosteroids, all patients fully recovered, and no unprovoked seizure attacks were observed (63).

#### 4.6. Brainstem and cerebellar lesions

One-third of MOGAD patients exhibit brainstem and cerebellar demyelination(34,64). Unlike MS, single brainstem attacks are uncommon in MOGAD and typically manifest with transverse myelitis, ADEM, or optic neuritis demyelinating lesions. While some patients can have no symptoms, most develop ataxia and diplopia, occasionally preceded by viral prodromes. It is essential to distinguish between lesions occurring in MS, AQP4-IgG-NMOSD, and MOGAD since treatment and prognosis differ significantly. Compared to MOGAD, AQP4-IgG-NMOSD typically manifests with nausea, vomiting, and hiccups due to the involvement of area postrema (34).

#### 4.7. Other clinical features

Given the likelihood of false-positive MOG-IgG results, particularly at low titers, it is prudent not to attribute unexpected clinical characteristics to MOGAD. However, specific MOG detection cell-based assays have expanded the clinical spectrum and include many atypical presentations. The following conditions were related to sufficiently high titers of MOG-IgG and occurring with the previously described manifestations:

- **Prolonged fever** – Although fever is not an uncommon sign in MOGAD patients, it is usually short-lived and precedes ADEM diagnosis by a few days. A recent study suggests that even prolonged fever lasting over two weeks can be an initial presentation of anti-MOG disease (65). The study included 12 cases, subdivided according to initial diagnosis as prolonged fever (PF) of unknown origin, aseptic meningitis, and PF in already diagnosed patients. Several cases developed ON or ADEM, and MOGAD diagnoses were established. Other papers report cases of aseptic meningitis with brain imaging revealing aberrant lesions in several locations. In the majority, headache, fever, and optic neuritis were among the most common early symptoms, with some preceding influenza-like clinical picture. A further investigation detected elevated MOG-IgG serum levels(66–68).
- **Peripheral nervous system involvement-** One study has demonstrated the association between MOGAD and peripheral neuropathy:19 of 271 MOGAD patients had PNS lesions, most frequently paresthesia and radicular pain, as well as polyneuropathy,myeloradiculitis, multifocal motor neuropathy, brachial neuritis and migrant sensory neuritis(69). Another study described an anti-MOG-positive patient who presented with peripheral neuropathy and numerous spinal and cerebral lesions (70). However, even after treatment, the patient experienced recurrence on multiple occasions, identical to chronic inflammatory demyelinating peripheral neuropathy (CIDP), and showed consistent positivity for

MOG-IgG on follow-up (70). Nonetheless, before assigning MOGAD a PNS phenotype, careful consideration is needed as further research should be conducted to determine whether this clinical manifestation is directly linked to MOG-IgG or another inflammatory etiology.

- **Anti-N-methyl-D-aspartate-receptor encephalitis-** anti-NMDAR-encephalitis is a frequent clinical manifestation in MOGAD patients. Several cases of anti-NMDAR encephalitis coexisting with anti-MOG antibodies have surfaced recently (71–75). Patients initially presented with headaches, fever, seizures, and cognitive impairment in two instances and tested positive for MOG-IgG(73,75). Those who showed double positivity for MOG-IgG and anti-NMDAR antibodies had an increased risk of developing leptomeningeal enhancement in addition to seizures and encephalopathy (71,74).
- **'Leukodystrophy-like' phenotype-** In a retrospective analysis of data collected from 31 pediatric patients, seven patients exhibited confluent and bilateral white matter abnormalities on MRI, resembling the demyelinating pattern of leukodystrophy diseases. Although all seven patients responded well to steroid treatment, four had a relapsing disease. The overall outcome was worse with this 'leukodystrophy-like' phenotype compared to children with other phenotypes, as demonstrated on follow-up examination, revealing persistent cognitive and behavioral issues and ongoing seizures(76). In a separate study, two patients presented with a progressive disease course, an unusual occurrence for MOGAD. MRI results revealed 'leukodystrophy-like' lesions with bilateral white matter involvement (77).

#### **4.8. Overlapping syndromes**

The discovery of MOG-IgG in other syndromes has raised the question of whether MOG also plays a role in non-demyelinating diseases. Unlike AQP4-IgG-NMOSD, for which a link with malignancies such as breast and lung cancer has been established (78), the incidence of MOGAD as a paraneoplastic disease is less well understood. One incidence of ovarian teratoma followed by MOG-IgG-positive optic neuritis has been described (79). The patient, identified with a right cystic mature teratoma, had the entire tumor excised. With high levels of MOG-IgG, optic neuritis of the left eye manifested eleven months after tumor resection and was preceded by viral infection. The relationship between the teratoma and the positive MOG-IgG has been substantiated because the teratoma expressed MOG-positive neuroectodermal tissue, and the MOG-IgG level fell considerably after excision and corticosteroid



therapy(79). Separate cohort studies found two other cases of ovarian teratomas with increased anti-MOG antibodies (64,80,81).

According to other research, two Japanese patients were diagnosed with the anti-MOG antibody-associated disease, meeting the criteria for Neuro- Behcet-Disease (NBD). Both cases presented with recurrent oral ulceration, with one patient developing acneiform nodules and the other with superficial thrombophlebitis (82). Additionally, the coexistence of MOGAD with other autoimmune disorders, such as systemic lupus erythematosus and, more recently, ankylosing spondylitis, have been reported(83,84). A possible connection between TNF $\alpha$  inhibitors and initiation of the demyelinating process is suggested; however, further studies are required to support this relationship (84).

#### **4.9. Association with COVID-19**

Since the beginning of the COVID-19 pandemic, multiple cases of neurological complications following SARS-CoV2 infection have been recorded. One patient was diagnosed with bilateral optic neuritis two weeks after a confirmed COVID-19 infection. The patient presented with bilateral eye pain and visual loss, and additional assessment revealed that his serum contained elevated levels of MOG-IgG. Methylprednisolone was administered, and consequently, the symptoms improved (85). A different patient with persistent headaches was eventually confirmed with MOG-positive encephalitis developing after COVID-19 infection(86). These data suggest a relationship between COVID-19-induced inflammation and a short-lived secondary autoimmune reaction characterized by transient MOG antibodies.

## **5. Evaluation and diagnosis**

### **5.1. When to screen for MOGAD**

The overlap in clinical and radiological manifestations between MOGAD, MS, and AQP4-IgG-NMOSD necessitates the presence of a MOG antibody for diagnosis. However, examining every patient with optic neuritis will increase the likelihood of false-positive results and overdiagnosis. Considering the diversity in treatment options and the fact that some can be harmful if not appropriate for the disease, this becomes a problem rather than a solution. Therefore, guidelines and recommendations for testing MOG-IgG were established by several studies and are summarized as follows(54,87):

- Acute disseminated encephalomyelitis (ADEM) or Multiphasic ADEM (MDEM) with brain MRI findings of significant, extensive T2 hyperintense lesions.

- Optic neuritis that is bilateral, recurrent with severe vision loss at attack or after, affecting the anterior optic pathway and presenting with optic disc swelling.
- Involvement of the conus medullaris at onset, with urinary, bowel, and erectile dysfunction symptoms persisting after therapy.
- Cortical encephalitis that is unilateral or bilateral with T2 hyperintense demyelination and swelling.

## **5.2. Diagnostic criteria**

The following diagnostic criteria for MOG antibody-associated disease were suggested by mayo clinic, Department of Neurology (44):

- Seropositivity for MOG-IgG by cell-based-assay
- Any of the following clinical manifestations:
  1. ADEM
  2. Optic neuritis or CRION
  3. Transverse myelitis
  4. Brain or brainstem involvement associated with MRI finding of demyelination.
  5. Any combination of the above
- Exclusion of alternative diagnosis

## **5.3. Investigation methods**

Once MOGAD is considered, the following investigation methods are applied to determine the full clinical and radiological status of the patients:

- Cell-based assay for MOG autoantibody detection
- Cerebrospinal fluid evaluation
- MRI of the orbits, brain, and spinal cord, with or without gadolinium enhancement.
- Optic coherence tomography

### **5.3.1 Cell-based assay**

The gold standard for diagnosing MOGAD is testing for MOG-IgG using a cell-based assay(88). The use of full-length human MOG expressed on human embryonic kidney cells (HEK293) as the target antigen improves the accuracy of test results(2). Sampling for patients' serum instead of CSF is favourable as MOG-IgG levels are low in the latter. Samples are then diluted to determine the titer of positivity, and the most significant dilution achieved is recorded. For most tests, the threshold for a positive result is a titer of 1:20 (89); however, this threshold is associated with a greater likelihood of false-positive results(89). The sampling timing is also crucial, as the highest levels are detected during

acute attacks, and the lowest are observed during remission, chronic phase, or following treatment(34). Therefore, repeated testing during acute episodes and treatment-free phases are reasonable and advisable when a patient's MOG-IgG result is negative, but clinical and radiological presentation strongly implies MOGAD as the diagnosis (87). MOG-IgG can also be detected by immunohistochemistry, ELISA, or western blotting, but these procedures aren't recommended due to their limited specificity for detecting the antibody(90). A cell-based assay's specificity ranges between 97.8 and 100 percent(89,91). The positive predictive value seems more variable and depends on disease prevalence in the population, and the titers considered. It can range from 72% to 94%; hence testing for this rare disease in low-likelihood settings should be avoided to prevent misdiagnosis(89).

### **5.3.2 Cerebrospinal fluid analysis**

Approximately fifty percent of MOGAD patients exhibit CSF pleocytosis dominated by lymphocytes and monocytes. Pleocytosis is more prevalent in acute attacks than between bouts(92,93). Additionally, the location and clinical presentation influence the degree of pleocytosis; in ADEM-anti MOG patients, pleocytosis can reach 75 percent, whereas, in MOGAD patients presenting with ON, pleocytosis is lower, reaching about 25 percent(46).

Moreover, the presence of oligoclonal bands should be examined when the clinical presentation is ambiguous. This CSF result is most consistent with a diagnosis of MS, as 88 percent of MS patients express it (94). Compared to MOGAD patients, oligoclonal bands are seen in 5 percent to 20 percent and are infrequent in those with an ON phenotype(92,93,95).

Also, up to fifty percent of patients may have high CSF protein levels, indicating a viral infection as an alternate diagnosis(95).

### **5.3.3 MRI findings**

- **MRI of the orbits**-Optic neuritis is the most common presentation of MOGAD in adults; hence, a focused orbital examination is more valuable than a generalized brain MRI for ON diagnosis. On MRI T2 weighted image, the extensive and swollen optic nerve is observed (96). The nerve enhancement is extensive and longitudinal, encompassing more than fifty percent of the nerve's length (97). It predominantly affects the anterior optic pathway and can extend to the fundus, which results in optic disc edema (97). Chiasmatic or retro-chiasmatic involvement is infrequent compared to AQP4-IgG-NMOSD, where it is a common

feature (96,97). Interestingly, isolated optic nerve sheath enhancement can be detected and may extend to the surrounding fatty tissue, which is rare in MS and AQP4-IgG-NMOSD (35,98). Compared to MS, where lesions are unilateral and limited in extent (97,99), optic neuritis in MOGAD shows bilateral enhancement in 25 to 50 percent of cases (32,38,97,100,101).

- **MRI of the brain-** Magnetic resonance imaging of MOGAD patients reveals both supratentorial and infratentorial abnormalities on T2 weighted images. Patients with ADEM phenotype display large and poorly demarcated ('fluffy') cortical or subcortical T2 hyperintense lesions of the white matter (44). Grey matter involvement is also known, particularly in the thalamus and basal ganglia, which overlaps with AQP4-IgG-NMOSD but is unusual in MS(43,44,102). As indicated on single-photon emission computed tomography (SPECT) scans, those with a cerebral cortical encephalitis phenotype had unilateral or bilateral cortical swelling and hyper-perfusion, as shown on single-photon emission computed tomography (SPECT) scans(61,103). When using gadolinium contrast, leptomeningeal enhancement appears to be a unique feature in individuals with MOGAD and is more common in children than adults (46,104). Other lesions tend to be patchy and more significant in enhancement than MS, with well-defined smaller lesions. In addition, lesions in the peduncles of the cerebellum are a common infratentorial abnormality seen in both MOGAD and MS patients (34,64,105). The small, well-defined lesions seen in MS patients, on the other hand, serve to distinguish them from MOGAD lesions, which are more extensive with hazy borders. Diffuse T2 hyperintense lesions in the brainstem are another noteworthy result, accounting for 20% of infratentorial abnormalities. They can affect the medulla, pons, or midbrain and, predictably, manifest as a pattern of large, poorly defined lesions similar to those seen in other parts of the brain(34). However, after treatment, lesions resolved in most patients, regardless of the affected area (37,47,97).
- **MRI of the spinal cord-** On sagittal MRI, a common finding in MOGAD patients is T2 hyperintense lesions of three or more vertebral segments, also known as longitudinally extensive transverse myelitis (LETM). Short lesions involving two vertebral segments or fewer are reported less frequently and may imply MS as the cause (51,52,81,106). Whether short or longitudinal, lesions are typically central, involving grey and white matter, and may be accompanied by cord swelling (37,51). Yet, some patients demonstrate sagittal linear hyperintensity and "H"-shaped hyperintensity on axial sequences, reflecting isolated grey matter involvement (106). This unique MRI feature can be helpful, as the same study

reports occurrence in 28% of MOGAD patients, 8% in AQP4-IgG-NMOSD, and an absence in MS patients (106). Interestingly, involvement of the lumbosacral area is more common in MOGAD patients than in MS or AQP4-IgG-NMOSD patients and is more frequently associated with persistent bladder dysfunction among MOGAD patients (37,51,106). Of particular importance, when leptomeningeal enhancement spreads to the nerve roots of the cauda equina and is associated with lower motor neuron signs, acute flaccid myelitis must be ruled out (69).

#### **5.3.4 Optical coherence tomography (OCT)**

OCT is a noninvasive imaging technology that creates retinal cross-sectional images using low-coherent light (107). It is imperative when evaluating optic neuritis in individuals with MOGAD, as the condition often affects the anterior optic pathway. The thickness of the combined macular ganglion cell layer and inner plexiform layers (mGCPIL), as well as the peripapillary retinal nerve fiber layer (pRNFL), are used to quantify the extent of retinal loss (108). OCT reveals pRNFL thickening at presentation, consisting of the common bilateral optic disc edema (109,110). In months to follow, both pRNFL and mGCPIL become thinner, although thinning of the latter is already prominent in the first few weeks (107,111). The single attacks in MOGAD patients do not result in severe damage but rather the cumulative changes that subsequently result in optical atrophy (109–111); therefore, MOGAD patients who experience recurring episodes should be evaluated and treated promptly to minimize the damage. Of important note, when comparing the visual outcomes, MOGAD patients show better visual acuity results than those with AQP4-IgG-NMOSD but are otherwise comparable to MS patients(109,110,112).

### **6. Differential diagnosis**

In adults and children, an event of CNS demyelination can represent one of many neuroinflammatory disorders, including AQP4-IgG-NMOSD, multiple sclerosis, and MOGAD. Distinguishing MOGAD from AQP4-IgG-NMOSD is relatively easy since both have reliable antibody biomarkers, and concurrent positivity is rare (57,87). However, it is more challenging to identify MOGAD from MS, mainly due to high false positives in low titers with MOGAD and the lack of distinctive antibody biomarkers in multiple sclerosis. Nevertheless, some clinical and radiological findings may help identify MOGAD from MS; for example, the absence of oligoclonal bands is predictable with anti-MOG positives but unlikely in MS patients as this is a common CSF finding (92,113). Additionally, abnormal residual T2 findings on MRI are more suggestive of MS since most lesions tend to

resolve over time in MOGAD patients (38,114), and rarely do MOGAD patients exhibit secondary progressive disease (115). Finally, as several MS therapeutic approaches are ineffective against MOGAD, these findings are especially noteworthy for patients with the recurring disease.

Jarius recognizes other findings that should encourage clinicians to reassess the diagnosis of MOGAD (87). They include sudden onset of symptoms that reaches maximum deficit in less than 4 hours (consider ischemic event) or symptoms worsening over weeks (consider progressive MS, tumor, sarcoidosis); lesion that is round and adjacent to lateral ventricle (Dawson finger-like periventricular lesion on MRI); dual positivity for AQP4 and MOG-IgG (rare occurrence and should indicate re-testing of both); And predominant involvement of peripheral nervous system (as MOG is mostly in CNS).

As MOGAD can affect many regions of the CNS, the clinical picture is typically diverse, with optic nerves, brain, and spinal cord involved solely or in combination. Thus, the list of possible alternative diagnoses extends to neuroborreliosis, neurotuberculosis, neurosyphilis; systemic lupus erythematosus; Behcet disease; anti-n methyl-D-aspartate encephalitis (can coexist with MOGAD); gliomatosis cerebri; posterior reversible encephalopathy syndrome and others (75,87). Notably, acute flaccid myelitis (AFM) should be considered in children with motor weakness and rapidly worsening myelitis (116). Typically, MRI reveals prominent T2 hyperintensity in the grey matter, which coincides with lower motor signs at presentation. Other characteristics comparable to MOGAD include LETM on MRI with a history of viral infection preceding the onset of neurological symptoms. Specifically, a history of prior CNS inflammation and a clinical course of more than ten days is more indicative of MOGAD than AFM (116).

## **7. Treatment**

MOGAD is a relatively new syndrome with heterogeneous clinical manifestations and low population prevalence. Due to these restrictions, no large multicentre treatment trials have been performed to date, and therapeutic regimens tend to resemble those of AQP4-IgG-NMOSD. Thus, the primary objective is to initiate treatment as soon as possible and identify those with a higher risk of relapse so that preventative measures can be taken.

### **7.1. Acute attacks**

initial treatment with high-dose intravenous methylprednisolone (IVMP) is recommended as most patients show excellent response with rapid resolution of symptoms (117). IVMP

is dosed at 1000 mg in adults or 20-30mg/kg/day in children for five consecutive days (118). Alternatively, oral prednisone at 1250 mg once daily can be considered in adults (118). Some studies report nearly complete recovery in over 50% of patients after administration of IVMP (81), and even more specifically in patients presenting with brainstem and cerebral cortical encephalitis as their initial attack (74). However, rapid reduction in glucocorticoid treatment is associated with an increased relapse rate, and slow tapering is advised (100,117).

Plasma exchange is suggested in patients with more severe attacks or if unresponsive to initial IVMP. It is administered as one exchange every other day for up to seven cycles in total. In children, intravenous immunoglobulin (IVIg) is the treatment of choice as second-line, given at a dose of 2 grams per kilogram over 2 to 5 days (119).

## **7.2. Attack prevention**

Unlike multiple sclerosis, attack-related disability in MOGAD patients is relapse-dependent (117), stressing the need for effective preventive intervention in patients at risk of relapse. Some experts agree that persistent MOG-IgG positivity is a reliable predictor of relapse risk (46), while others contend that such a judgment should be based on a comprehensive clinical picture (117). Standard immunomodulating medications or immunosuppressants, such as oral corticosteroids (OCS), repeated rounds of intravenous immunoglobulin (IVIg), azathioprine (AZA), rituximab (RTX), mycophenolate mofetil (MMF) and tocilizumab, are available as therapeutic options (100,117,118). Once again, there are no randomized controlled trials for preventive therapy in MOGAD, and therapeutic strategies are established from knowledge of treatment efficacy in other CNS autoimmune diseases.

- o **Oral immunosuppressants-** AZA and MMF are commonly used oral immunosuppressants for MOGAD patients. They suppress immune system activity by interfering with B and T cell proliferation through different mechanisms (120,121). In retrospective observational data, relapse rates were reduced in patients treated with either AZA or MMF, but still, up to 50% of patients relapsed (64,100,122–125). In addition, the use of azathioprine or mycophenolate mofetil was proven to decrease the dosage of corticosteroids and their side effects, as demonstrated in studies of other autoimmune diseases (126). Also, when combined with prednisone, better results were achieved, as they can prevent early relapse until immunosuppressants take effect (118).
- o **Azathioprine-** AZA is a prodrug that belongs to the thiopurines drug class. Nonenzymatically, it is transformed into 6-mercaptopurine, which is then

metabolized into active and non-active compounds by different enzymes. Incorporating the active metabolites (thioguanine nucleotides) in the DNA of lymphocytes interfere with their proliferation and subsequently results in immunosuppression. Thiopurine-s- methyltransferase enzyme activity generates inactive metabolites, and its deficit can push the reaction towards the HPRT pathway, resulting in adverse side effects. Thus, testing for TPMT enzyme levels is required in all patients before starting treatment to adjust dosing or switch to an alternative drug (120,127).

In patients with regular TPMT activity, the typical dose is between 2 and 2.5 mg per kg given orally as a single or divided dose (127). Regular monitoring of complete blood count (CBC) and liver and kidney function is recommended before and after therapy as toxicity is associated with elevated liver enzymes and kidney damage (118). Other adverse effects include rashes, infections, cytopenia, and hypersensitivity and rarely can increase the risk for malignancies (skin or lymphoma) (120,127).

- o **Mycophenolate mofetil-** MMF is a prodrug of mycophenolic acid with a potent immunosuppressive effect. It is classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanine nucleotides. It thus interferes with B and T cell proliferation (121,128). In the first two weeks, the dose in adults is 500 mg per oral, twice daily, and subsequently reaches a maintenance dose of 1000 mg twice daily. In children, the dose is 650 mg per body surface area (118). Like azathioprine, regular CBC and liver and kidney monitoring are recommended before and after therapy. Adverse effects are primarily associated with gastrointestinal disorders ranging from mild diarrhea and abdominal pain to more severe conditions like gastrointestinal bleeding and perforation (129).
- o **Prednisone-** Prednisone is a synthetic glucocorticoid that mediates anti-inflammatory and immunosuppressive effects (130). Initial doses of up to 1mg/kg per day (118), followed by a slow taper, are a common and convenient strategy for acute attack prevention in MOGAD patients. However, its prolonged use as maintenance therapy is restricted due to the vast adverse effects (100,122,123). Examples include increased risk of infections, delayed wound healing, skin fragility, mood changes, cushingoid appearance, edema, adrenal suppression, and osteoporosis (131). Vitamin D and calcium supplements are advised to decrease the risk for osteoporosis, together with antibiotics as prophylaxis for infections (118).



- o **Intravenous immunoglobulin therapy**- the effectiveness of IVIG infusions as maintenance therapy in MOGAD patients was promising by multiple studies (100,122,132). Recent research compared relapse rates of IVIG with other medications and demonstrated favorable treatment response among this group with the lowest relapse rates of 20%. On the contrary, annualized relapse rates with RTX, AZA, and MMF exceeded 50% (123). The lack of immunosuppressive effect associated with increased risk of infection is another advantage IVIG has over the other medications (133). However, limitations on usage arise partly due to its high cost and other side effects that can harm a subset of patients. The risk of renal failure is particularly concerning as IVIG increases the risk for thromboembolic events (133). Also, an allergic response could rise in IgA deficient patients if IgA levels are not checked before administration and adjusted to IgA depleted infusions.  
Cycles of IVIG are administered over one to five days, once a month, with a dose ranging between 1 to 2 g/kg (118). Subcutaneous application of immunoglobulin therapy is feasible and enables treatment maintenance at home. They are particularly beneficial in children due to the difficulty of IV access, however, its usage in MOGAD patients has not been thoroughly investigated (134,135).
- o **Rituximab**- RTX is a monoclonal antibody that depletes B cells by targeting CD20 on B cells (136). The effectiveness of rituximab as preventive therapy is inconsistent. Several studies suggest a reduction in the annualized risk of relapse, while others report comparable results to AQP4-IgG-NMOSD patients, namely the occurrence of new attacks within a few weeks of the initial infusion (41,100,122–124,137,138). Nonetheless, due to the risk of secondary hypogammaglobulinemia after treatment, CBC and specifically IgA, IgG levels should be monitored as well as CD19 and CD20 due to RTX-induced depletion of both (139–141).
- o **Tocilizumab**- tocilizumab is a monoclonal antibody that targets interleukin 6, which is necessary for B-cell maturation and antibody production (142). Effectiveness in lowering relapse rates is somewhat less than that observed for RTX (143). Adverse effects such as cytopenia and risk for infections necessitate regular monitoring of complete blood counts, with attention to the liver function test (118).

## **8. Prognosis**

MOGAD has a variable clinical presentation, with either a monophasic or multiphasic pattern. More recent data indicate that recurrent attacks are common among MOGAD patients, especially if presenting with optic neuritis as their initial episode(16,32). Other investigations revealed that MOG-IgG positivity's persistence could predict relapsing disease compared to patients with transient positivity (44,122,144). However, it is still controversial whether serial testing for MOG antibodies should be utilized in practice to support such a claim. Generally, monophasic disease is more likely among pediatric MOGAD patients, notably if ADEM manifested as their first episode. On the contrary, children with optic neuritis as the first sign or with attack onset at an older age had a greater probability of recurrence (145).

The attack severity in MOGAD is comparable to AQP4-IgG-NMOSD and initially appears disproportionate, with blindness, gait problems, and bladder dysfunction commonly present in the acute phase (32,146). Disability at first and subsequent attacks is measured by the extended disability status scale (EDSS). The score ranges between 0 and 10; 6 or more designate the need for walking aid and 10 as death resulting from the attack (147). In one retrospective cohort of 61 MOGAD patients with a median follow-up of nearly 15 years, more than 60% of patients had EDSS scores <3 at their last visit, pointing to favourable outcomes (148). Another study of 29 patients, with a median follow-up of 14 years, demonstrated an EDSS score of six or greater in only 7 percent of patients (149). Similarly, in studies with a shorter follow-up time, bowel and bladder sphincters and erectile dysfunction were more common than visual, motor, or cognitive impairments (32). However, secondary progression like MS is uncommon in MOGAD patients (115), in which MRI findings after multiple relapses demonstrate full recovery, while patients with MS had persistent lesions on MRI scan even after symptoms resolve (38,114).

Although attacks in MOGAD can be detrimental, they rarely result in death. In the same cohort of 29 patients, one patient died after multiple CNS attacks, despite proper treatment initiation (149). Another study reported death due to brain herniation despite the appropriate treatment with corticosteroids. A subsequent autopsy revealed several cortical and subcortical demyelinating lesions in the frontal, parietal and temporal lobes, with histopathological testing confirming MOG-IgG presence (20). One study analyzing causes of death among AQP4-IgG NMOSD patients identified the infection as the leading cause, presumably due to prolonged immunosuppressive therapy (150). As immunosuppression was proved to be successful for relapse prevention in MOGAD

patients, comparing the benefits of such achievement to the risk of infection underlines the need for incident cohort studies on MOGAD patients to acquire a better knowledge of the disease prognosis.

## **9. Conclusion**

MOGAD was previously thought to be a variant of NMOSD; however, pathohistological investigations have demonstrated a different inflammatory mechanism that in some aspects resembles that of MS or AQP4-IgG-NMOSD but still carries distinctive features, making it a separate diagnosis. In addition, the recent advances in MOGAD research have revealed the disease's heterogeneous clinical presentation, as it can affect multiple brain regions, the optic nerves, and the spinal cord. Nonetheless, as a novel inflammatory demyelinating disorder of the CNS, further research is required to determine its incidence worldwide, what other diagnostic approaches could be applied, and how the current diagnostic tools could be improved. Ultimately, randomized controlled trials should be conducted to establish the most effective treatment strategies to minimize the side effects and decrease the relapse likelihood.

## **10. Acknowledgements**

My sincere gratitude goes to my mentor, prof. dr. sc. Nina Barišić, dr. med, for her guidance, patience, and immense knowledge that helped me write this thesis. I am grateful for gaining a deeper understanding of this important topic in pediatric neurology. I am also thankful to the first and second expert committee members, prof. dr. sc. Irena Senečić-Čala and prof. dr. sc. Marija Jelušić for their evaluation and helpful feedback.

Above all, my deepest gratitude goes to my family, whose unwavering support, encouragement, and belief in me helped me tremendously during my studies. I owe my success, especially to my father, who is always there to support me and keep me motivated and eager to learn on this journey to becoming a doctor.

## **11. References**

1. Egg R, Reindl M, Deisenhammer F, Linington C, Berger T. Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis [Internet]. Vol. 7, Multiple Sclerosis. 2001. Available from: [www.arnoldpublishers.com/journals](http://www.arnoldpublishers.com/journals)
2. O'Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. *Nat Med* [Internet]. 2007;13(2):211–7. Available from:

<http://www.nature.com/naturemedicine>

3. dos Passos GR, Oliveira LM, da Costa BK, Apostolos-Pereira SL, Callegaro D, Fujihara K, et al. MOG-IgG-associated optic neuritis, encephalitis, and myelitis: Lessons learned from neuromyelitis optica spectrum disorder. *Front Neurol* [Internet]. 2018;9(APR):1. Available from: [www.frontiersin.org](http://www.frontiersin.org)
4. Stadelmann C, Timmler S, Barrantes-Freer A, Simons M. Myelin in the Central Nervous System: Structure, Function, and Pathology. *Physiol Rev* [Internet]. 2019;99:1381–431. Available from: [www.prv.org](http://www.prv.org)
5. Brunner C, Lassmann H, Waehnelde T V., Matthieu J -M, Linington C. Differential Ultrastructural Localization of Myelin Basic Protein, Myelin/Oligodendroglial Glycoprotein, and 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase in the CNS of Adult Rats. Vol. 52, *Journal of Neurochemistry*. 1989.
6. Gaspera B Della, Pham-Dinh D, Roussel G, Nussbaum J-L, Dautigny A. Membrane topology of the myelin/oligodendrocyte glycoprotein. Vol. 258, *Eur. J. Biochem*. 1998.
7. Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein. *J Neurochem*. 1999 Jan;72(1):1–9.
8. Burger D, Steck AJ, Bernard CCA, Rosbo NK De. Human Myelin / Oligodendrocyte Glycoprotein : A New Member of the L2 / HNK-1 Family. *J Neurochem*. 1993;
9. Morise J, Takematsu H, Oka S. The role of human natural killer-1 (HNK-1) carbohydrate in neuronal plasticity and disease. *Biochim Biophys Acta - Gen Subj* [Internet]. 2017;1861(10):2455–61. Available from: <http://dx.doi.org/10.1016/j.bbagen.2017.06.025>
10. Pham-Dinh D, Mattei MG, Nussbaum JL, Roussel G, Pontarotti P, Roeckel N, et al. Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex. *Proc Natl Acad Sci U S A*. 1993;90(17).
11. Kroepfl JF, Viise LR, Charron AJ, Linington C, Gardinier M V. Investigation of myelin/oligodendrocyte glycoprotein membrane topology. *J Neurochem*. 1996;67(5):2219–22.
12. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. *Nat Rev Immunol* [Internet].

- 2002;2(2):116–26. Available from: [www.nature.com/reviews/immunol](http://www.nature.com/reviews/immunol)
13. Zettl UK, Pröbstel A-K, Marignier R, Berger T, Di Pauli F. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders? *Front Immunol* | [www.frontiersin.org](http://www.frontiersin.org) [Internet]. 2018;9:2753. Available from: [www.frontiersin.org](http://www.frontiersin.org)
  14. Jarius S, Metz I, König FB, Ruprecht K, Reindl M, Paul F, et al. Screening for MOG-IgG and 27 other anti-glia and anti-neuronal autoantibodies in “pattern II multiple sclerosis” and brain biopsy findings in a MOG-IgG-positive case. *Mult Scler*. 2016;22(12):1541–9.
  15. Lington C, Bradl M, Lassmann H, Brunner C, Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Vol. 130, *American Journal of Pathology*. 1988.
  16. Netravathi M, Holla VV, Nalini A, Yadav R, Vengalil S, Oommen AT, et al. Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder. *J Neurol* [Internet]. 2021 Apr 1 [cited 2022 Jun 9];268(4):1419–33. Available from: <https://link.springer.com/article/10.1007/s00415-020-10300-z>
  17. Spadaro M, Winklmeier S, Beltrán E, Macrini C, Höftberger R, Schuh E, et al. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. *Ann Neurol*. 2018;84(2):315–28.
  18. Peschl P, Bradl M, Höftberger R, Berger T, Reindl M. Myelin oligodendrocyte glycoprotein: Deciphering a target in inflammatory demyelinating diseases. *Front Immunol* [Internet]. 2017;8(MAY):1. Available from: [www.frontiersin.org](http://www.frontiersin.org)
  19. Bradl M, Reindl M, Lassmann H. Mechanisms for lesion localization in neuromyelitis optica spectrum disorders. *Curr Opin Neurol* [Internet]. 2018;31(3):325–33. Available from: [www.co-neurology.com](http://www.co-neurology.com)
  20. Höftberger R, Guo Y, Eoin ·, Flanagan P, Sebastian Lopez-Chiriboga · A, Endmayr V, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. *Acta Neuropathol* [Internet]. 2020;139:875–92. Available from: <https://doi.org/10.1007/s00401-020-02132-y>
  21. Takai Y, Misu T, Kaneko K, Chihara N, Narikawa K, Tsuchida S, et al. Myelin

- oligodendrocyte glycoprotein antibody-associated disease: An immunopathological study. *Brain* [Internet]. 2020;143(5):1431–46. Available from: <https://academic.oup.com/brain/article/143/5/1431/5837518>
22. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. *J Exp Med*. 2005;202(4):473–7.
  23. de Mol CL, Wong YYM, van Pelt ED, Wokke BHA, Siepmann TAM, Neuteboom RF, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. *Mult Scler J* [Internet]. 2020;26(7):806–14. Available from: <https://doi.org/10.1177/1352458519845112>
  24. O’Connell K, Hamilton-Shield A, Woodhall M, Messina S, Mariano R, Waters P, et al. Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK. *J Neurol Neurosurg Psychiatry*. 2020;91(10):1126–8.
  25. Senanayake B, Jitprapaikulsan J, Aravinthan M, Wijesekera JC, Ranawaka UK, Riffsy MT, et al. Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka. *J Neurol Neurosurg Psychiatry* [Internet]. 2019;90(12):1381–3. Available from: <http://jnnp.bmj.com/>
  26. Hyun JW, Lee HL, Jeong WK, Lee HJ, Shin JH, Min JH, et al. Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseases. *Mult Scler J* [Internet]. 2021;27(6):964–7. Available from: <https://doi.org/10.1177/1352458520948213>
  27. Kim S-H, Pin Yong K, Yung Hor J, Asgari N, Nakashima I, Broadley SA, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. *Front Neurol* | [www.frontiersin.org](http://www.frontiersin.org) [Internet]. 2020;1:501. Available from: [www.frontiersin.org](http://www.frontiersin.org)
  28. Bruijstens AL, Yi Y, Wong M, Van Pelt DE, Van Der Linden PJE, Haasnoot GW, et al. HLA association in MOG-IgG-and AQP4-IgG-related disorders of the CNS in the Dutch population From the Department of Neurology (. *Neurol Neuroimmunol Neuroinflamm*. 2020;7:702.
  29. Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: A systematic review. Vol. 71, *Neurology*. 2008.
  30. Brill L, Ganelin-Cohen E, Dabby R, Rabinowicz S, Zohar-Dayana E, Rein N, et al.

- Age-Related Clinical Presentation of MOG-IgG Seropositivity in Israel. *Front Neurol*. 2021 Jan 21;11.
31. Willis MD, Robertson NP. Myelin oligodendrocyte glycoprotein antibody-associated disease: characterising clinical disease. *J Neurol* [Internet]. 2018;265(8):1950–2. Available from: <https://doi.org/10.1007/s00415-018-8963-z>
  32. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. *BRAIN a J Neurol* [Internet]. 2017; Available from: <https://academic.oup.com/brain/article/140/12/3128/4608963>
  33. Francis A, Palace J, Fugger L. MOG antibody-associated disease after vaccination with ChAdOx1 nCoV-19. *Lancet Neurol* [Internet]. 2022;21(3):217–8. Available from: [http://dx.doi.org/10.1016/S1474-4422\(22\)00043-6](http://dx.doi.org/10.1016/S1474-4422(22)00043-6)
  34. Banks SA, Morris PP, Chen JJ, Pittock SJ, Sechi E, Kunchok A, et al. Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. Vol. 92, *Journal of Neurology, Neurosurgery and Psychiatry*. 2021. p. 384–90.
  35. Chen JJ, Flanagan EP, Jitprapaikulsan J, López-ASS, Fryer JP, Leavitt JA, et al. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiological Clues, and Outcome. *Am J Ophthalmol*. 2018;195(1):8–15.
  36. Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children. *Neurology*. 2006;67(2):258–62.
  37. Kitley J, Waters P, Woodhall M, Isabel Leite M, Murchison A, BCh B, et al. Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies A Comparative Study. *JAMA Neurol* [Internet]. 2014;71(3):276–83. Available from: <https://jamanetwork.com/>
  38. Denève M, Biotti D, Patsoura S, Ferrier M, Meluchova Z, Mahieu L, et al. MRI features of demyelinating disease associated with anti-MOG antibodies in adults. *J Neuroradiol*. 2019;46(5):312–8.
  39. Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: A systematic review of 122 cases reported. *J Neurol*. 2014;261(1):17–26.

40. Liu H, Zhou H, Wang J, Xu Q, Wei To cite S, Br al J, et al. Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy. *Br J Ophthalmol* [Internet]. 2019;103:1423–8. Available from: <http://bjo.bmj.com/>
41. Armangue T, Olivé-Cirera G, Martínez-Hernandez E, Sepulveda M, Ruiz-Garcia R, Muñoz-Batista M, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. *Lancet Neurol*. 2020;19(3):234–46.
42. Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. *Mult Scler J*. 2012;19(10):1261–7.
43. Jurynczyk M, Geraldes R, Probert F, Woodhall MR, Waters P, Tackley G, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. *Brain* [Internet]. 2017;140(3):617–27. Available from: <https://academic.oup.com/brain/article/140/3/617/2996233>
44. Sebastian López-Chiriboga A, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, et al. Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders Supplemental content CME Quiz at [jamanetwork.com/learning](http://jamanetwork.com/learning) and CME Questions page 1448. *JAMA Neurol* [Internet]. 2018;75(11):1355–63. Available from: <https://jamanetwork.com/>
45. Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. *J Neurol Neurosurg Psychiatry* [Internet]. 2015;86(3):265–72. Available from: <http://dx.doi.org/10.1136/jnnp-2014-308346>
46. Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. *Neurology* [Internet]. 2018 May 22 [cited 2022 May 17];90(21):e1858–69. Available from: <https://pubmed.ncbi.nlm.nih.gov/29695592/>
47. Salama S, Khan M, Shanечи A, Levy M, Izbudak I. MRI differences between MOG antibody disease and AQP4 NMOSD. *Mult Scler J* [Internet]. 2020;26(14):1854–65. Available from: <https://doi.org/10.1177/1352458519893093>



48. Rössler T, Benetou C, Wright S, Duignan S, Lascelles K, Robinson R, et al. Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis. *Mult Scler J* [Internet]. 2020;26(3):333–42. Available from: <https://doi.org/10.1177/1352458518823486><https://doi.org/10.1177/1352458518823486>
49. Krishnan C, Kaplin AI, Deshpande DM, Pardo CA, Kerr DA. TRANSVERSE MYELITIS: PATHOGENESIS, DIAGNOSIS AND TREATMENT. Vol. 9, *Frontiers in Bioscience*. 2004.
50. Chen JJ, Tariq Bhatti M. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. *Curr Opin Neurol*. 2020;33(1):47–54.
51. Mariano R, Messina S, Kumar K, Kuker W, Leite MI, Palace J. Comparison of Clinical Outcomes of Transverse Myelitis among Adults with Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease. *JAMA Netw Open* [Internet]. 2019;2(10). Available from: <https://jamanetwork.com/>
52. Ciron J, Cobo-Calvo A, Audoin B, Bourre B, Brassat D, Cohen M, et al. Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. *Mult Scler J* [Internet]. 2020;26(8):936–44. Available from: <https://doi.org/10.1177/1352458519849511>
53. Goh C, Desmond PM, Phal PM. MRI in Transverse Myelitis. *J Magn Reson Imaging*. 2014;40:1267–79.
54. Flanagan AEP, Bch MB, Tillema J. Myelin oligodendrocyte glycoprotein antibody-associated disease ( MOGAD ): Clinical features and diagnosis. *UpToDate*. 2021;1–21.
55. Tan CT. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Vol. 85, *Neurology*. 2015.
56. Prasad S, Chen J. What you need to know about aqp4, mog, and nmosd. *Semin Neurol*. 2019;39(6):718–31.
57. Mao Z, Lu Z, Hu X, Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between mog antibodypositive and aqp4 antibody-positive nmo spectrum disorders. *Neurology*. 2014;83(12):1122–3.
58. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Myelin-

- oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. *Neurology*. 2012;79(12):1273–7.
59. Ramanathan S, Reddel SW, Henderson A, Parratt JDE, Barnett M, Gatt PN, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. *Neurol Neuroimmunol Neuroinflamm*. 2014;1:40.
  60. Höftberger R, Sepulveda M, Armangue T, Blanco Y, Rostásy K, Cobo Calvo A, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. *Mult Scler [Internet]*. 2015;21(7):866–74. Available from: <http://www.sagepub.co.uk/>
  61. Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. *Neurol Neuroimmunol Neuroinflamm*. 2017;4:322.
  62. Budhram A, Mirian A, Le C, Hosseini-Moghaddam SM, Sharma M, Nicolle MW. Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome. *J Neurol [Internet]*. 2019 Oct 1 [cited 2022 Jun 27];266(10):2481–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/31243540/>
  63. Wang YF, Liu XW, Lin JM, Liang JY, Zhao XH, Wang SJ. The Clinical Features of FLAIR-Hyperintense Lesions in Anti-MOG Antibody Associated Cerebral Cortical Encephalitis with Seizures: Case Reports and Literature Review. *Front Immunol*. 2021 Jun 11;12.
  64. Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N, et al. MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. *J Neuroinflammation*. 2016;13(1).
  65. Udani V, Badheka R, Desai N. Prolonged Fever: An Atypical Presentation in MOG Antibody-Associated Disorders. *Pediatr Neurol [Internet]*. 2021;122:1–6. Available from: <https://doi.org/10.1016/j.pediatrneurol.2021.03.006>
  66. Narayan RN, Wang C, Sguigna P, Husari K, Greenberg B. Atypical Anti-MOG syndrome with aseptic meningoencephalitis and pseudotumor cerebri-like presentations. *Mult Scler Relat Disord [Internet]*. 2019;27(June 2018):30–3. Available from: <https://doi.org/10.1016/j.msard.2018.10.003>
  67. Suzuki T, Maekawa K, Matsuo K, Yamasaki M, Shibata M, Takahashi T, et al.

- Aseptic Meningitis as an Initial Manifestation of Anti-myelin Oligodendrocyte Glycoprotein Antibody-associated Disease. *Intern Med* [Internet]. 2019;58:3319–21. Available from: <http://internmed.jp>
68. Leinert J, Neumaier-Probst E, Kutschke G, Tenenbaum T. MOG antibody associated demyelinating syndrome presenting as aseptic meningitis in a 6-year-old boy. *Mult Scler Relat Disord* [Internet]. 2020;41(March):102050. Available from: <https://doi.org/10.1016/j.msard.2020.102050>
  69. Rinaldi S, Davies A, Fehmi J, Beadnall HN, Wang J, Hardy TA, et al. Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders. *Neurol Neuroimmunol Neuroinflamm*. 2021;8:924.
  70. Nakamura T, Kaneko K, Watanabe G, Harashima S, Kawasaki E, Tsukita K, et al. Myelin oligodendrocyte glycoprotein-IgG-positive, steroid-responsive combined central and peripheral demyelination with recurrent peripheral neuropathy. *Neurol Sci* [Internet]. 2021;42(3):1135–8. Available from: <https://doi.org/10.1007/s10072-020-04822-7>
  71. Kunchok A, Flanagan EP, Krecke KN, Chen JJ, Caceres JA, Dominick J, et al. MOG-IgG1 and coexistence of neuronal autoantibodies. *Mult Scler J* [Internet]. 2021;27(8):1175–86. Available from: <https://doi.org/10.1177/1352458520951046><https://doi.org/10.1177/1352458520951046>
  72. Sarigecili E, Cobanogullari MD, Komur M, Okuyaz C. A rare concurrence: Antibodies against Myelin Oligodendrocyte Glycoprotein and N-methyl-D-aspartate receptor in a child. *Mult Scler Relat Disord* [Internet]. 2019;28:101–3. Available from: <https://doi.org/10.1016/j.msard.2018.12.017>
  73. Amano E, Machida A, Kanazawa N, Iizuka T. Cerebrospinal fluid MOG-antibodies in anti-NMDA receptor encephalitis with leptomeningeal enhancement. *Neurol Sci* [Internet]. 2020;41(9):2635–8. Available from: <https://doi.org/10.1007/s10072-020-04343-3>
  74. Wang L, Zhang Bao J, Zhou L, Zhang Y, Li H, Li Y, et al. Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China. *Eur J Neurol*. 2019;26:168–74.
  75. Fujimori J, Takahashi T, Kaneko K, Atobe Y, Nakashima I. Anti-NMDAR

- encephalitis may develop concurrently with anti-MOG antibody-associated bilateral medial frontal cerebral cortical encephalitis and relapse with elevated CSF IL-6 and CXCL13. *Mult Scler Relat Disord*. 2021;47:13–5.
76. Hacoen Y, Rossor T, Mankad K, Chong W 'Kling,' Lux A, Wassmer E, et al. 'Leukodystrophy-like' phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease. *Dev Med Child Neurol*. 2018;60(4):417–23.
  77. Yazbeck E, Maurey H, Leroy C, Horellou P, Napuri S, Lali M, et al. Progressive Leukodystrophy-Like Demyelinating Syndromes with MOG-Antibodies in Children: A Rare Under-Recognized Phenotype. *Neuropediatrics*. 2021;52(4):337–40.
  78. Sepúlveda M, Sola-Valls N, Escudero D, Rojc B, Barón M, Hernández-Echebarría L, et al. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. *Mult Scler J [Internet]*. 2018;24(13):1753–9. Available from: <https://doi.org/10.1177/1352458517731914>
  79. Wildemann B, Jarius S, Franz J, Ruprecht K, Reindl M, Stadelmann C. MOG-expressing teratoma followed by MOG-IgG-positive optic neuritis. *Acta Neuropathol [Internet]*. 2021;141:127–31. Available from: <https://doi.org/10.1007/s00401-020-02236-5>
  80. Cobo-Calvo Á, Ruiz A, Hyacintha D'indy , Poulat A-L, Carneiro · Maryline, Philippe N, et al. MOG antibody-related disorders: common features and uncommon presentations. *J Neurol*. 2017;3:1945–55.
  81. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. *J Neuroinflammation*. 2016;13(1).
  82. Fujimori J, Takahashi T, Matsumoto Y, Fujihara K, Takai Y, Misu T, et al. Two Japanese cases of anti-MOG antibody-associated encephalitis that mimicked neuro-Behçet's disease. *J Neuroimmunol [Internet]*. 2019;334(May):577002. Available from: <https://doi.org/10.1016/j.jneuroim.2019.577002>
  83. Philippe A Bilodeau , Vinayak Kumar, Andrew E Rodriguez, Clarence T Li, Catalina Sanchez-Alvarez, Uma Thanarajasingam NLZ and EPF. MOG-IgG myelitis coexisting with systemic lupus erythematosus in the post-partum setting. Vol. 26, *Multiple Sclerosis Journal*. 2020. p. 997–1000.

84. Luo W, Li R, Chang Y, She H, Kermode AG, Qiu W. Myelin oligodendrocyte glycoprotein antibody-associated disorders coexisting with ankylosing spondylitis: Potential association between demyelination and tumor necrosis factor inhibitors. *Mult Scler Relat Disord*. 2021;51(January):2020–2.
85. Sawalha K, Adeodokun S, Kamoga GR. COVID-19-Induced Acute Bilateral Optic Neuritis. *J Investig Med High Impact Case Reports* [Internet]. 2020;8. Available from: <https://doi.org/10.1177/2324709620976018>
86. Durovic E, Bien C, Bien CG, Isenmann S. MOG antibody-associated encephalitis secondary to Covid-19: case report. Vol. 21, *BMC Neurology*. 2021.
87. Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. *J Neuroinflammation* [Internet]. 2018;15(1). Available from: <https://doi.org/10.1186/s12974-018-1144-2>
88. Waters P, Woodhall M, O KC, Reindl M, Lang B, Sato DK, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. *Neurol Neuroimmunol Neuroinflamm*. 2015;2:89.
89. Sechi E, Buciu M, Pittock SJ, Chen JJ, Fryer JP, Jenkins SM, et al. Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. *JAMA Neurol* [Internet]. 2021;78(6):741–6. Available from: <https://jamanetwork.com/>
90. Markus Reindl, PhD,\* Kathrin Schanda, MSc, Mark Woodhall, PhD, Fiona Tea, BSc (Hons), Sudarshini Ramanathan, FRACP, PhD, Jessica Sagen, BA, James P. Fryer, MS, John Mills, PhD, Bianca Teegen, PhD, Swantje Mindorf, MSc, Nora Ritter, MSc, Ulrike Krummrei, P P. International multicenter examination of MOG antibody assays. *Neurol Neuroimmunol Neuroinflamm*. 2020;7(e):674.
91. Waters PJ, Komorowski L, Woodhall M, Lederer S, Majed M, Fryer J, et al. A multicenter comparison of MOG-IgG cell-based assays. *Neurology*. 2019;92(11):E1250–5.
92. Jarius S, Pellkofer H, Siebert N, Korporal-Kuhnke M, Hümmert MW, Ringelstein M, et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. *J Neuroinflammation* [Internet]. 2020;17(1). Available from: <https://doi.org/10.1186/s12974-020-01824-2>

93. Jarius S, Lechner C, Wendel EM, Baumann M, Breu M, Schimmel M, et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. *J Neuroinflammation*. 2020 Sep 3;17(1).
94. Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: A meta-analysis of prevalence, prognosis and effect of latitude. *J Neurol Neurosurg Psychiatry*. 2013;84(8):909–14.
95. Sechi E, Buciuic M, Flanagan EP, Pittock SJ, Banks SA, Lopez-Chiriboga AS, et al. Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. *Mult Scler Relat Disord* [Internet]. 2021;47:102638. Available from: <https://doi.org/10.1016/j.msard.2020.102638>
96. Biotti D, Bonneville F, Tournaire E, Ayrignac · Xavier, Clarisse ·, Dallièrè C, et al. Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. *J Neurol*. 2017;264:2173–5.
97. Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson APD, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. *Mult Scler* [Internet]. 2016;22(4):470–82. Available from: <http://www.sagepub.co.uk/>
98. Sebastian Lopez-Chiriboga A, Van Stavern G, Flanagan EP, Pittock SJ, Fryer J, Tariq Bhatti M, et al. Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis. *Neuro-Ophthalmology* [Internet]. 2020;44. Available from: <https://doi.org/10.1080/01658107.2019.1607883>
99. Carra-Dalliere C, Menjot de Champfleury N, Ayrignac X, Labauge P. Optic chiasm and oculomotor nerves involvement in active multiple sclerosis. *J Neuroradiol* [Internet]. 2020;47(1):62–4. Available from: <https://doi.org/10.1016/j.neurad.2018.10.007>
100. Ramanathan sudarshini, Mohammad shekeeb, Tantsis esther, Kim Nguyen T, Merheb V, Fung V, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. *J Neurol Neurosurg Psychiatry* [Internet]. 2018;89:127–37. Available from: <http://dx.doi.org/10.1136/jnnp-2017-316880>

101. Winter A, Chwalisz B. MRI Characteristics of NMO, MOG and MS Related Optic Neuritis. *Semin Ophthalmol* [Internet]. 2020;35(7–8):333–42. Available from: <https://doi.org/10.1080/08820538.2020.1866027>
102. Tenenbaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: A long-term follow-up study of 84 pediatric patients. *Neurology*. 2002;59(8):1224–31.
103. Budhram A, Mirian · A, Le · C, Hosseini-Moghaddam · S M, Sharma · M, Nicolle · M W. Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome. *J Neurol* [Internet]. 2019;266:2481–7. Available from: <https://doi.org/10.1007/s00415-019-09440-8>
104. Gadde JA, Wolf DS, Keller S, Gombolay GY. Rate of Leptomeningeal Enhancement in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody–Associated Encephalomyelitis. *J Child Neurol*. 2021;36(11):1042–6.
105. Fujimori J, Takai Y, Nakashima I, Sato DK, Takahashi T, Kaneko K, et al. Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies. *J Neurol Neurosurg Psychiatry*. 2017;88(6):534–6.
106. Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, et al. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody CME Quiz at [jamanetwork.com/learning](http://jamanetwork.com/learning). *JAMA Neurol* [Internet]. 2019;76(3):301–9. Available from: <https://jamanetwork.com/>
107. Lotan I, Oertel FC, Chien C, Asseyer S, Paul F, Stiebel-Kalish H. Practical recognition tools of immunoglobulin G serum antibodies against the myelin oligodendrocyte glycoprotein-positive optic neuritis and its clinical implications. *Clin Exp Neuroimmunol*. 2021;12(1):42–53.
108. Podoleanu AG. Optical coherence tomography. *J Microsc*. 2012;247(3):209–19.
109. Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. *J Neuroinflammation*. 2016;13(282):1–10.
110. Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte

- glycoprotein and aquaporin-4 antibodies: A comparative study. *J Neurol Neurosurg Psychiatry* [Internet]. 2016;87(4):446–8. Available from: <http://jnnp.bmj.com/>
111. Zhao G, Chen · Qian, Huang Y, Li · Zhenxin, Sun · Xinghuai, Lu P, et al. Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China. *J Neurol* [Internet]. 2018;265:33–40. Available from: <https://doi.org/10.1007/s00415-017-8651-4>
  112. Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, Alba-Arbalat S, Llufríu S, Blanco Y, et al. Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. *Ther Adv Neurol Disord* [Internet]. 2016;9(5):436–40. Available from: <http://tan.sagepub.com>
  113. Kaneko K, Kazutoshi Sato D, Nakashima I, Ogawa R, Akaishi T, Takai Y, et al. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications Neuro-inflammation. *J Neurol Neurosurg Psychiatry* [Internet]. 2018;89:927–36. Available from: <http://jnnp.bmj.com/>
  114. Shahriari M, Sotirchos ES, Newsome SD, Yousem DM. MOGAD: How it differs from and resembles other neuroinflammatory disorders. *Am J Roentgenol* [Internet]. 2021;216(4):1031–9. Available from: [www.ajronline.org%7C1031](http://www.ajronline.org%7C1031)
  115. Jarius S, Ruprecht K, Stellmann JP, Huss A, Azyzenberg I, Willing A, et al. MOG-IgG in primary and secondary chronic progressive multiple sclerosis: A multicenter study of 200 patients and review of the literature. *J Neuroinflammation* [Internet]. 2018;15(1). Available from: <https://doi.org/10.1186/s12974-018-1108-6>
  116. Murphy OC, Messacar K, Benson L, Bove R, Carpenter JL, Crawford T, et al. Acute flaccid myelitis: cause, diagnosis, and management. *Lancet*. 2021;397(10271):334–46.
  117. Marignier R, Hacohen Y, Cobo-Calvo A, Pröbstel AK, Aktas O, Alexopoulos H, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. *Lancet Neurol*. 2021;20(9):762–72.
  118. Flanagan AEP, Bch MB, Tillema J. Myelin oligodendrocyte glycoprotein antibody-associated disease ( MOGAD ): Treatment and prognosis. *UpToDate*. 2022;(Iv):1–17.



119. Hacoheh Y, Banwell B. Treatment Approaches for MOG-Ab-Associated Demyelination in Children. *Curr Treat Options Neurol*. 2019;21(1).
120. UpToDate. Azathioprine : Drug information. Vol. 15. 2022. 1–50 p.
121. UpToDate. Mycophenolate mofetil (cellcept) and mycophenolate sodium (myfortic): drug information [Internet]. 2021. 1–54 p. Available from: [https://www-uptodate-com.ezproxy.ub.unimaas.nl/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information?search=treatment myasthenia gravis&topicRef=5175&source=see\\_link#F198647](https://www-uptodate-com.ezproxy.ub.unimaas.nl/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information?search=treatment%20myasthenia%20gravis&topicRef=5175&source=see_link#F198647)
122. Hacoheh Y, Yi Wong Y, Lechner C, Jurynczyk M, Wright S, Konuskan B, et al. Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Supplemental content. *JAMA Neurol* [Internet]. 2018;75(4):478–87. Available from: <https://jamanetwork.com/>
123. Chen JJ, Flanagan EP, Bhatti MT, Jitrapaikulsan J, Dubey D, Lopez Chiriboga A (sebastian) S, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. *Neurology*. 2020;95(2):E111–20.
124. Cobo-Calvo A, Sepúlveda M, Rollot F, Armangué T, Ruiz A, Maillart E, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. *J Neuroinflammation* [Internet]. 2019;16(1). Available from: <https://doi.org/10.1186/s12974-019-1525-1>
125. Zhou J, Lu X, Zhang Y, Ji T, Jin Y, Xu M, et al. Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination. *Mult Scler Relat Disord*. 2019;28(August 2018):4–10.
126. Sukanjanapong S, Thongtan D, Kanokrungrsee S, Suchonwanit P, Chanprapaph K. A Comparison of Azathioprine and Mycophenolate Mofetil as Adjuvant Drugs in Patients with Pemphigus: A Retrospective Cohort Study. *Dermatol Ther (Heidelb)* [Internet]. 2020;10(1):179–89. Available from: <https://doi.org/10.6084/>
127. Oranus Mohammadi<sup>1</sup>; Thamer A. Kassim<sup>2</sup>. Azathioprine - PubMed [Internet]. Statpearls Publisher. Statpearls Publisher; 2022 [cited 2022 Jun 8]. Available from: <https://pubmed.ncbi.nlm.nih.gov/31194347/>
128. Li S, Ren H, Xu Y, Xu T, Zhang Y, Yin H, et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders A prospective study Class of Evidence Criteria for rating therapeutic and

- diagnostic studies. *Neurol Neuroimmunol Neuroinflamm*. 2020;7:705.
129. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: Aetiology, incidence and management. *Drug Saf*. 2001;24(9):645–63.
  130. UpToDate. Prednisone : Drug information. 2022. 1–55 p.
  131. Yana Puckett; Aishah Gabbar; Abdullah A. Bokhari. Prednisone - StatPearls - NCBI Bookshelf [Internet]. [cited 2022 Jun 13]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK534809/>
  132. Domingo-Santos, Á., Sepúlveda, M., Matarazzo, M., Calleja-Castaño, P., Ramos-González, A., Saiz, A., & Benito-León J. Intravenous Immunoglobulin Therapy in a Patient With Anti-Myelin Oligodendrocyte Glycoprotein-Seropositive Neuromyelitis Optica. *Wolters Kluwer Heal*. 2016;39(6):1–2.
  133. Spurlock NK, Prittie JE. A review of current indications, adverse effects, and administration recommendations for intravenous immunoglobulin. *J Vet Emerg Crit Care*. 2011;21(5):471–83.
  134. Quinti I, Pierdominici M, Marziali M, Giovannetti A, Donnanno S, Chapel H, et al. European surveillance of immunoglobulin safety - Results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries. *Clin Immunol*. 2002;104(3):231–6.
  135. Kobrynski L. Subcutaneous immunoglobulin therapy: A new option for patients with primary immunodeficiency diseases. *Biol Targets Ther* [Internet]. 2012;6:277–87. Available from: <http://dx.doi.org/10.2147/BTT.S25188>
  136. Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, et al. Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. *Mult Scler Relat Disord*. 2020;44.
  137. Durozard P, Rico A, Boutiere C, Maarouf A, Lacroix R, Cointe S, et al. Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases. *Ann Neurol* [Internet]. 2020 Feb 1 [cited 2022 Jun 13];87(2):256–66. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/ana.25648>
  138. Bai P, Zhang M, Yuan J, Zhu R, Li N. A comparison of the effects of rituximab versus other immunotherapies for MOG-IgG-associated central nervous system demyelination: A meta-analysis. *Mult Scler Relat Disord*. 2021;53(April).

139. Avouac A, Maarouf A, Stellmann JP, Rico A, Boutiere C, Demortiere S, et al. Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody-Associated Diseases. *Neurol Neuroimmunol neuroinflammation*. 2021;8(3).
140. Jones JD, Hamilton BJ, Rigby WFC. Rituximab Mediates Loss of CD19 on B Cells in the Absence of Cell Death. *ARTHRITIS Rheum*. 2012;64(10):3111–8.
141. Baranzini D, Leppert H-C, Von B, Derstine A, Abounasr SL, Hauser SE, et al. Sclerosis Patients CD20-Expressing T Cells in Multiple Rituximab Efficiently Depletes Increased. 2022; Available from: <http://www.jimmunol.org/content/193/2/580>
142. UpToDate. Tocilizumab : Drug information. 2022. 1–33 p.
143. Rigal J, Pugnet G, Ciron J, Lépine Z, Biotti D. Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: A case-series. *Mult Scler Relat Disord* [Internet]. 2020;46(September):102483. Available from: <https://doi.org/10.1016/j.msard.2020.102483>
144. Waters P, Fadda G, Woodhall M, O'mahony J, Brown RA, Castro DA, et al. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes Supplemental content. *JAMA Neurol* [Internet]. 2020;77(1):82–93. Available from: <https://jamanetwork.com/>
145. Fadda G, Armangue T, Hacoheh Y, Chitnis T, Banwell B. Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care. *Lancet Neurol* [Internet]. 2021;20(2):136–49. Available from: [http://dx.doi.org/10.1016/S1474-4422\(20\)30432-4](http://dx.doi.org/10.1016/S1474-4422(20)30432-4)
146. Jitprapaikulsan J, Chen JJ, Flanagan EP, Tobin WO, Fryer JP, Weinshenker BG, et al. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. *Ophthalmology* [Internet]. 2018;125(10):1628–37. Available from: <https://doi.org/10.1016/j.ophtha.2018.03.041>
147. Van Munster CEP, Bernard •, Uitdehaag MJ. Outcome Measures in Clinical Trials for Multiple Sclerosis. *CNS Drugs*. 2017;31:217–36.
148. Deschamps R, Pique J, Ayrignac X, Collongues N, Audoin B, Zéphir H, et al. The long-term outcome of MOGAD: An observational national cohort study of 61 patients. *Eur J Neurol* [Internet]. 2021 May 1 [cited 2022 Jun 8];28(5):1659–64.

Available from: <https://pubmed.ncbi.nlm.nih.gov/33528851/>

149. A. Sebastian Lopez-Chiriboga, MD Elia Sechi, MD Marina Buciuc, MD John J. Chen, MD, PhD Sean J. Pittock, MD Claudia F. Lucchinetti, MD Eoin P. Flanagan M. Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G–Associated Disorder. *JAMA Neurol* [Internet]. 2020;77.  
Available from: <https://jamanetwork.com/>
150. Du Q, Shi Z, Chen H, Zhang Y, Wang J, Qiu Y, et al. Mortality of neuromyelitis optica spectrum disorders in a Chinese population. *Ann Clin Transl Neurol*. 2021;8(7):1471–9.

## **12. Biography**

Aya Younes was born on August 7<sup>Th</sup>, 1996, in Beer Sheva, Israel. In 2014, Aya graduated with honors from high school. The following year, she worked as a school assistant and a tutor for a teenager diagnosed with neurofibromatosis type 1. During 2016-2022, Aya studied general medicine at the University of Zagreb, School of medicine, Croatia. During her studies, she attended clinical rotations in The Department of Gynecology, Pediatric Neurology, and Family medicine.